When should therapeutic intervention take place for men on active surveillance?

The fact of the matter is that, as yet, we don’t have a good answer for this question, and it may be many years before we do. The reasons for this are numerous, but we are beginning to get some of the information we need to clarify the situation. … READ MORE …

Published data on Klotz’s active surveillance series at c. 20 years

In a report published on line on Monday, in the Journal of Clinical Oncology, Klotz et al. have now provided peer-reviewed data from their nearly 20-year-long series of patients managed on active surveillance. … READ MORE …

Formal update on Sunnybrook active surveillance data at AUA annual meeting

Over the weekend, Klotz et al. provided interesting new information in the third and most recent, formal update of the prospective data from the active surveillance series being monitored at Sunnybrook Cancer Center in Toronto, Canada. … READ MORE …

Prostate cancer risk calculators and the decision to have a prostate biopsy

A new paper in the Journal of Clinical Oncology provides some interesting insights into the relative merits of the two major prostate cancer risk calculators widely used today in North America: the original PCPT-based risk calculator (PRC) and the Sunnybrook risk calculator (SRC). … READ MORE …